Theravance Biopharma TBPH Enterprise value

Enterprise value at other companies

Gyre Therapeutics, Inc.GYRE

$694.84M+6.1%

Rigel PharmaceuticalsRIGL

$543.41M+96.3%

LQD

Liquidia CorporationLQDA

$3.11B+184%

Royalty PharmaRPRX

$33B+45.9%

Zevra Therapeutics, Inc.ZVRA

$703.89M+36.7%

Aurinia PharmaceuticalsAUPH

$2.08B+83.9%

FAQ

What is Theravance Biopharma's enterprise value?

Theravance Biopharma (TBPH) reported enterprise value of $588.13M in Q1 2026.

How has Theravance Biopharma's enterprise value changed year-over-year?

Theravance Biopharma's enterprise value increased by 55.1% year-over-year, from $379.31M to $588.13M.

What is the long-term trend for Theravance Biopharma's enterprise value?

Over 5 years (2020 to 2025), Theravance Biopharma's enterprise value has grown at a -6.0% compound annual growth rate (CAGR), from $1.12B to $822.98M.

What does enterprise value mean?

Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.